Journal of Jilin University(Medicine Edition) ›› 2025, Vol. 51 ›› Issue (3): 653-662.doi: 10.13481/j.1671-587X.20250310
• Research in basic medicine • Previous Articles Next Articles
Yuling GU,Cui ZHENG,Yunxian TANG(
)
Received:2024-07-18
Accepted:2024-09-07
Online:2025-05-28
Published:2025-07-18
Contact:
Yunxian TANG
E-mail:guyuling95@163.com
CLC Number:
Yuling GU,Cui ZHENG,Yunxian TANG. Inhibitory effect of silencing of circadian rhythm gene TIMELESS on immune escape of ovarian cancer SK-OV-3 cells and its mechanism[J].Journal of Jilin University(Medicine Edition), 2025, 51(3): 653-662.
Tab. 2
Levels of IFN-γ and TNF-α in supernatant of co-culture systerm cells in various groups after transfected with oe-NC and oe-PD-L1 detected by ELISA method [n=3, x±s, ρB/(ng·L-1)]"
| Group | IFN-γ | TNF-α |
|---|---|---|
| BC/T | 72.89±4.55 | 106.78±6.01 |
| Si-NC+oe-NC/T | 74.03±6.13 | 109.44±10.03 |
| Si-TIM/T | 134.83±11.28* | 209.53±9.59* |
| Si-TIM+oe-PD-L1/T | 92.57±4.25△ | 153.55±8.23△ |
| [1] | SONG J, SOKOLL L J, ZHANG Z, et al. VCAM-1 complements CA-125 in detecting recurrent ovarian cancer[J]. Clin Proteomics, 2023, 20(1): 25. |
| [2] | LAMPROPOULOU D I, PAPADIMITRIOU M, PAPADIMITRIOU C, et al. The role of EMT-related lncRNAs in ovarian cancer[J]. Int J Mol Sci, 2023, 24(12): 10079. |
| [3] | PREETAM S, MONDAL S, PRIYA S, et al. Targeting tumour markers in ovarian cancer treatment[J]. Clin Chim Acta, 2024, 559: 119687. |
| [4] | YIN S S, GAO F H. Molecular mechanism of tumor cell immune escape mediated by CD24/siglec-10[J]. Front Immunol, 2020, 11: 1324. |
| [5] | JIANG X J, WANG J, DENG X Y, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape[J]. Mol Cancer, 2019, 18(1): 10. |
| [6] | CAI Y D, CHIU J C. Timeless in animal circadian clocks and beyond[J]. FEBS J, 2022, 289(21): 6559-6575. |
| [7] | VIPAT S, MOISEEVA T N. The TIMELESS roles in genome stability and beyond[J]. J Mol Biol, 2024, 436(1): 168206. |
| [8] | COLANGELO T, CARBONE A, MAZZARELLI F, et al. Loss of circadian gene Timeless induces EMT and tumor progression in colorectal cancer via Zeb1-dependent mechanism[J]. Cell Death Differ, 2022, 29(8): 1552-1568. |
| [9] | XING X, GU F, HUA L Y, et al. TIMELESS promotes tumor progression by enhancing macrophages recruitment in ovarian cancer[J]. Front Oncol, 2021, 11: 732058. |
| [10] | 粟连秀, 陈静平, 杨达平, 等. 沉默生物钟基因Timeless对卵巢癌SKOV3细胞凋亡和侵袭能力的影响[J]. 中国病理生理杂志, 2019, 35(7): 1169-1175. |
| [11] | DONG X R, DAI H J, LIN Y P, et al. TIMELESS upregulates PD-L1 expression and exerts an immunosuppressive role in breast cancer[J]. J Transl Med, 2023, 21(1): 400. |
| [12] | AKTAR N, CHEN Y T, ABBAS M, et al. Understanding of immune escape mechanisms and advances in cancer immunotherapy[J]. J Oncol, 2022, 2022: 8901326. |
| [13] | SAVID-FRONTERA C, VIANO M E, BAEZ N S, et al. Exploring the immunomodulatory role of virtual memory CD8+T cells: Role of IFN gamma in tumor growth control[J]. Front Immunol, 2022, 13: 971001. |
| [14] | GILES J R, GLOBIG A M, KAECH S M, et al. CD8+T cells in the cancer-immunity cycle[J]. Immunity, 2023, 56(10): 2231-2253. |
| [15] | QIN Y Y, BAO X Y, ZHENG M Z. CD8+T-cell immunity orchestrated by iNKT cells[J]. Front Immunol, 2023, 13: 1109347. |
| [16] | WANG X M, ZHANG Y, ZHENG J, et al. LncRNA UCA1 attenuated the killing effect of cytotoxic CD8+T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway[J]. Cancer Immunol Immunother, 2021, 70(8): 2235-2245. |
| [17] | 杨 婷, 郑锦秀, 高书华, 等. 钙连蛋白(CNX)通过促进MHCⅠ表达增强CD8+T细胞对结直肠癌细胞的杀伤作用[J]. 细胞与分子免疫学杂志, 2022, 38(2): 97-102. |
| [18] | QIN R, ZHAO C, WANG C J, et al. Tryptophan potentiates CD8+T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation[J]. J Immunother Cancer, 2021, 9(7): e002840. |
| [19] | CHANG W H, LAI A G. Timing gone awry: distinct tumour suppressive and oncogenic roles of the circadian clock and crosstalk with hypoxia signalling in diverse malignancies[J]. J Transl Med, 2019, 17(1): 132. |
| [20] | GAO Y Y, WU Y W, ZHANG N M, et al. IDH1 gene mutation activates Smad signaling molecules to regulate the expression levels of cell cycle and biological rhythm genes in human glioma U87-MG cells[J]. Mol Med Rep, 2021, 23(5): 354. |
| [21] | YANG Y C, TANG X Z, LIN Z J, et al. An integrative evaluation of circadian gene TIMELESS as a pan-cancer immunological and predictive biomarker[J]. Eur J Med Res, 2023, 28(1): 563. |
| [22] | ZHOU J H, ZHANG Y H, ZOU X W, et al. Aberrantly expressed timeless regulates cell proliferation and cisplatin efficacy in cervical cancer[J]. Hum Gene Ther, 2020, 31(5/6): 385-395. |
| [23] | HOEKSTRA M E, VIJVER S V, SCHUMACHER T N. Modulation of the tumor micro-environment by CD8+ T cell-derived cytokines[J]. Curr Opin Immunol, 2021, 69: 65-71. |
| [24] | ZHU D, XU R D, HUANG X P, et al. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1[J]. Cell Death Differ, 2021, 28(6): 1773-1789. |
| [25] | CHA J H, YANG W H, XIA W Y, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1[J]. Mol Cell, 2018, 71(4): 606-620.e7. |
| [26] | DUMITRU A, DOBRICA E C, CROITORU A, et al. Focus on PD-1/PD-L1 as a therapeutic target in ovarian cancer[J]. Int J Mol Sci, 2022, 23(20): 12067. |
| [27] | CHARDIN L, LEARY A. Immunotherapy in ovarian cancer: thinking beyond PD-1/PD-L1[J]. Front Oncol, 2021, 11: 795547. |
| [28] | KHATOON E, PARAMA D, KUMAR A, et al. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy[J]. Life Sci, 2022, 306: 120827. |
| [29] | CHEN J X, YI X J, GAO S X, et al. The possible regulatory effect of the PD-1/PD-L1 signaling pathway on Tregs in ovarian cancer[J]. Gen Physiol Biophys, 2020, 39(4): 319-330. |
| [1] | Hong LI,Panpan YU,Zouyu ZHAO,Chongfeng SUN,Hui QIAO,Ping YANG. Expression of GSTO1 in ovarian cancer tissue and effect of N-glycosylation site mutations on biological behaviors of epithelial ovarian cancer cells [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 469-482. |
| [2] | Xiaoshuang HE,Lina XU,Mei CUI,Yu ZHAO,Bei WANG,Zheng HUANG,Yuchao WANG,Wenyan XIN,Chao WU. Effects of lncRNA DUXAP8 in lung cancer A549 cells-derived exosomes on lung cancer cell growth and its mechnism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 958-967. |
| [3] | Chunying TIAN,Ting LI,Yuanyuan CHEN,Wenyan LIU,Ruiyao LI,Xiuyan YU. Detection of ST2, CA125, and HE4 levels in serum of ovarian cancer patients and their clinical significances [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 778-784. |
| [4] | Shuo ZHANG,Yunxiu XIA,Weiwei CHEN,Hongliang DONG,Bingjie CUI,Cuilan LIU,Zhiqiang LIU,Fei WANG,Jing DU. Effect of over-expression of NR2F2 on biological behaviors of human ovarian cancer SKOV3 cells [J]. Journal of Jilin University(Medicine Edition), 2025, 51(1): 58-67. |
| [5] | Qinghui WANG,Bo LI,Chuancui HU,Mingchao NIE,Xiaomei ZHENG. Effects of miR-107 on regulation of immune escape and taxol resistance of ovarian cancer cells [J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 734-743. |
| [6] | LI Songyan, LIN Dongjing, YU Yang, LIU Shibing, XU Lu, SUN Qi, XU Ye. Effect of silencing sirtuin 3 on resveratrol-induced apoptosis of human ovarian cancer SKOV3 cells [J]. Journal of Jilin University(Medicine Edition), 2020, 46(01): 45-49. |
| [7] | ZHANG Baoyue, ZHANG Junnong. Synergetic effect of epidermal growth factor receptor tyrosine kinase inhibitor kaempferol in combination with tarceva on apoptosis of ovarian cancer cells [J]. Journal of Jilin University Medicine Edition, 2016, 42(01): 31-35. |
| [8] |
ZHAO Qiang, ZHOU Tong, ZHAI Ying-Xian, WANG Jian-Wei, JIN Zhao-Hui, SHI Ying-Ai.
Expressions of MIF and VEGF in ovarian cancer tissues and their correlations with microvascular density [J]. J4, 2010, 36(4): 713-716. |
| [9] | DONG Li-hua, LIU Feng, LI Yan-bo, FU Shi-b. Effects of recombinant plasmid pEgr-p53 transfected stably in combination with X-irradiation on cell cycle progression and proliferation in human SKOV-3 tumor cells in vitro [J]. J4, 2008, 34(3): 357-360. |
|